Table 1. Demographic data of Pfizer and AstraZeneca vaccine groups
Ann Clin Microbiol 2022;25:85-95. Antibody detection in healthcare workers after vaccination with two doses of the BNT162b2 or ChAdOx1 vaccine Download table Demographic data Pfizer BNT162b2 AstraZeneca ChAdOx1 Sex Male Female Total Male Female Total 41 (33.9) 80 (66.1) 121 (100.0) 38 (32.5) 79 (67.5) 117 (100.0) Age (yr) […]
Table 2. Antimicrobial susceptibility patterns of 23 C. striatum isolates
Ann Clin Microbiol 2022;25:79-84. Antimicrobial susceptibility patterns and clinical characteristics of Corynebacterium striatum cases from 2018 to 2021 Download table Isolates Minimum inhibitory concentration (ug/mL) and interpretation Penicillin G Cefotaxime Meropenem Erythromycin Ciprofloxacin Trimethoprim/Sulfamethoxazole Vancomycin 1 > 32 R NT > 32 R 64 R NT > 32 R 0.75 S 2 1 S NT […]
Table 1. Clinical features and outcome of C. striatum cases between 2018 and 2021
Ann Clin Microbiol 2022;25:79-84. Antimicrobial susceptibility patterns and clinical characteristics of Corynebacterium striatum cases from 2018 to 2021 Download table Demographic data Pfizer BNT162b2 AstraZeneca ChAdOx1 Sex Male Female Total Male Female Total 41 (33.9) 80 (66.1) 121 (100.0) 38 (32.5) 79 (67.5) 117 (100.0) Age (yr) 20 – 29 5 (12.2) 19 (23.8) 24 […]
Table 1. Distribution of Exdia Ag test result according to cycle threshold (Ct) values of Real-Q assay (RdRp gene)
Ann Clin Microbiol 2022;25:73-78. On-field evaluation of exdia COVID-19 antigen point-of-care testing in the emergency department during the COVID-19 pandemic Download table Ct value of Real-Q assay (RdRp gene) Exdia Ag result Positive No. (%) Negative No. (%) ≤ 15 (n = 59) 58 (98.3) 1 (1.7) 15 < Ct ≤ 20 (n = 41) […]
Table 1. New meropenem-vaborbactam breakpoints in Enterobacterales, P.aeruginosa
Ann Clin Microbiol 2022;25:67-72. EUCAST v.12.0 review focused on changes Download table Organism Breakpoint S ≥ R < ATU Enterobacterales Zone diameter (mm) 20 29 15-19 P. aeruginosa 14 14 – Abbreviations: S, susceptible; R, resistance; ATU, area of technical uncertainly.
Table 2. New EUCAST v.12.0 clinical breakpoint organism-antimicrobial agent for anaerobic bacteria
Ann Clin Microbiol 2022;25:67-72. EUCAST v.12.0 review focused on changes Download table Organism Antimicrobial agent Bacteroides spp. Piperacillin-tazobactam, Meropenem, Clindamycin, Metronidazole Prevotella spp. Benzylpenicillin, Piperacillin-tazobactam, Meropenem, Clindamycin, Metronidazole F. necrophorum Benzylpenicillin, Piperacillin-tazobactam, Meropenem, Clindamycin, Metronidazole C. perfringens Benzylpenicillin, Piperacillin-tazobactam, Meropenem, Vancomycin, Clindamycin, Metronidazole C. acnes Benzylpenicillin, Piperacillin-tazobactam, Meropenem, Vancomycin, Clindamycin C. difficile Vancomycin, Metronidazole, Fidaxomicin […]
Table 3. Revised EUCAST v.12.0 clinical breakpoints
Ann Clin Microbiol 2022;25:67-72. EUCAST v.12.0 review focused on changes Download table (A) Disk diffusion method: revised zone diameter breakpoints (mm), ATU Organism Antimicrobial agent S ≥ R < ATU P. aeruginosa Meropenem (indications other than meningitis) 20 14 – Meropenem (meningitis) 20 20 Pseudomonasspp. Levofloxacin 50 18 S. epidermidisand S.lugdunensis Cefoxitin (screen only) 27 […]
Table 1. Resistance to carbapenem and ciprofloxacin with corresponding resistance genes
Ann Clin Microbiol 2022;25:53-59. Current prevalence of the crpP gene in carbapenemase-producing Pseudomonas aeruginosa blood isolates in Korea Download table Isolates Phenotype (ZD) Genotype IPM MEM CIP CRP PMQR gyrA parC F0020PA0023 R (11) R (10) R (6) blaGES-9 aac(6′)-Ib-cr Thr83Ile Ser87Leu A0020PA0022 R (7) R (6) R (6) blaGES-5 aac(6′)-Ib-cr, crpP Thr83Ile Ser87Leu A0020PA0005 […]
Table 1. Comparison between CA-CDI and HA-CDI groups
Ann Clin Microbiol 2022;25:47-52. Clinical and microbiological risk factors for community-associated Clostridioides difficile infections Download table Variables CA-CDI (n = 127) HA-CDI (n = 265) P-value Age (yr) 66.9±18.9 72.1±13.5 0.0064 Sex, male 51 (40.2) 120 (45.3) 0.3386 Charlson comorbidity index 2.4±2.1 2.7±1.9 0.1109 Associated disease Biliary tract disease 3 (2.4) 8 (3.0) 0.7133 Cancer […]
Table 2. Patient characteristics of four cases with UL54 mutations alone
Ann Clin Microbiol 2022;25:41-46. Antiviral resistance in human cytomegalovirus due to UL54 mutations without UL97 mutations Download table Patient No. Sex Age (yr) Underlying disease CMV disease Outcome UL54 mutations 6 Female 15 MDS, HaploPBSCT Pneumonia Retinitis Encephalitis Expired F412L 11 Female 18 AA, HaploPBSCT Pneumonia Encephalitis Expired V715M/L501I 14 Female 18 AA, HaploPBSCT Encephalitis […]